Caffeine test in predicting flutamide-induced hepatic injury in patients with prostate cancer

Prostate Cancer and Prostatic Diseases

Volumn 5, Issue 2, 2002, Pages 128-131

  Ozono, S ^a   Yamaguchi, A ^a   Mochizuki, H ^a   Kawakami, T ^a   Fujimoto, K ^a   Otani, T ^a   Yoshida, K ^a   Ichinei, M ^b   Yamashita, T ^b   Hirao, Y ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

^b NIPPON KAYAKU CO LTD   (Japan)

Author keywords

Caffeine test; CYP1A2 activity; Flutamide; Hepatic injury

Indexed keywords

1,7 DIMETHYLURIC ACID; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CAFFEINE; CYTOCHROME P450 1A2; FLUTAMIDE; PARAXANTHINE; ANTIANDROGEN; DIAGNOSTIC AGENT; PHOSPHODIESTERASE INHIBITOR;

ARTICLE; CLINICAL ARTICLE; COFFEE; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; LIVER FUNCTION; LIVER INJURY; MALE; METABOLITE; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; URINALYSIS; URINE LEVEL; AGED; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; LIVER DISEASE; MIDDLE AGED; PREDICTION AND FORECASTING; PROSTATE TUMOR;

AGED; ANDROGEN ANTAGONISTS; CAFFEINE; CYTOCHROME P-450 CYP1A2; FLUTAMIDE; HUMAN; LIVER DISEASES; MALE; MIDDLE AGE; PHOSPHODIESTERASE INHIBITORS; PREDICTIVE VALUE OF TESTS; PROSTATIC NEOPLASMS; HUMANS; MIDDLE AGED;

EID: 0035996416     PISSN: 13657852     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.pcan.4500564     Document Type: Article

References (17)

1. Clinical evaluation of flutamide, a pure antiandrogen, in prostatic cancer phase II dose-finding study
2. A case of fulminant hepatitis caused by antiandrogen, flutamide in a patient with prostate cancer
3. A case of flutamide-induced acute cholestatic hepatitis
4. Fatal hepatic failure following hepatitis caused by flutamide: A case report
5. Toxicity of the antiandrogen flutamide in isolated rat hepatocytes
6. Metabolic activation of the nitroaromatic antiandrogen flutamide by rat and human cytochromes P-450, including forms belonging to the 3A and 1A subfamilies
7. In vitro effects of fluoroquinolone anti-bacterial agents on flutamide metabolism in human liver microsomes
8. Assessment of liver metabolic function. Clinical implications
9. Phenotyping of drug-metabolizing enzymes in adults: A review of in vivo cytochrome P450 phenotyping probes
10. Phenotyping of CYP1A2 in Japanese population by analysis of caffeine urinary metabolites: Absence of mutation prescribing the phenotype in the CYP1A2 gene
11. Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites
12. Caffeine metabolism in a healthy Spanish population: N-acetylator phenotype and oxidation pathways
13. Total androgen blockade for prostate cancer
14. A prospective randomized multicenter study of chlormadinone acetate versus flutamide in total androgen blockade for prostate cancer
15. Study of flutamide-induced liver disorders
16. Flutamide-induced hepatic disorders and serum concentrations of flutamide and its metabolites in patients with prostate cancer
17. Risk factor of liver disorders caused by flutamide-statistical analysis using multivariate logistic regression analysis